Authors: O'Shaughnessy, JA Blum, J Moiseyenko, V Jones, SE Miles, D Bell, D Rosso, R Mauriac, L Osterwalder, B Burger, HU Laws, S

Citation: Ja. O'Shaughnessy et al., Randomized, open-label, phase II trial of oral capecitabine (Xeloda((R))) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer, ANN ONCOL, 12(9), 2001, pp. 1247-1254

Authors: Hoff, PM Ansari, R Batist, G Cox, J Kocha, W Kuperminc, M Maroun, J Walde, D Weaver, C Harrison, E Burger, HU Osterwalder, B Wang, AO Wong, R

Citation: Pm. Hoff et al., Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study, J CL ONCOL, 19(8), 2001, pp. 2282-2292

Authors: Van Cutsem, E Findlay, M Osterwalder, B Kocha, W Dalley, D Pazdur, R Cassidy, J Dirix, L Twelves, C Allman, D Seitz, JF Scholmerich, J Burger, HU Verweij, J

Citation: E. Van Cutsem et al., Capecitabine, an oral fluoropyrimidine carbamate with substantial activityin advanced colorectal cancer: Results of a randomized phase II study, J CL ONCOL, 18(6), 2000, pp. 1337-1345

Authors: Villalona-Calero, MA Weiss, GR Burris, HA Kraynak, M Rodrigues, G Drengler, RL Eckhardt, SG Reigner, B Moczygemba, J Burger, HU Griffin, T Von Hoff, DD Rowinsky, EK

Citation: Ma. Villalona-calero et al., Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies, J CL ONCOL, 17(6), 1999, pp. 1915-1925

Authors: Blum, JL Jones, SE Buzdar, AU LoRusso, PM Kuter, I Vogel, C Osterwalder, B Burger, HU Brown, CS Griffin, T

Citation: Jl. Blum et al., Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer, J CL ONCOL, 17(2), 1999, pp. 485-493